The Allergic Rhinitis Therapeutics Market is Forecast to Decline until 2018

Wednesday 7 March 2012, Amsterdam

The report is an essential source of information and analysis on the global allergic rhinitis therapeutics market, identifying the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global allergic rhinitis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The Allergic Rhinitis Therapeutics Market is Forecast to Decline until 2018

An analysis estimated the allergic rhinitis therapeutics market (the US, the UK, France, Germany, Italy, Spain and Japan) to be worth $4,406.6m in 2010. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 1.3% for the next eight years to reach $3,981.0m by 2018. The market declined during 2005–2010 owing to the patent expiries of major drugs such as Zyrtec (cetirizine) and Omnaris (ciclesonide) in 2007 and 2010 respectively. The decline during the forecast period can be attributed to the expected patent expiry of Astelin (azelastine hydrochloride), Nasonex (mometasone furoate), Nasacort AQ (triamcinolone acetonide) and Rhinocort Aqua (budesonide) in the year 2011, 2014, 2016 (US) and 2017 respectively. Nasacort AQ will loose its patent protection in the Europe in 2017. In addition, Astepro (azelastine hydrochloride), Xyzal (levocetirizine) and Singulair (montelukast sodium) are set to loose their patent protection in the year 2012.

This decline in the market can be slightly offset by the expected launch of Dymista (combination of azelastine hydrochloride and fluticasone propionate), Omnaris HFA (ciclesonide nasal aerosol in a hydrofluoroalkane (HFA) formulation) and Qnaze HFA (beclomethasone dipropionate hydrofluoroalkane) in the year 2012. The expected launch of a novel immunotherapeutic agent, Actair (house dust mite desensitization tablet) might have a significant impact on the market.

The Allergic Rhinitis Therapeutics Market has Low Unmet Need with Significant Potential for Novel Immunotherapeutic Agents

The allergic rhinitis therapeutics market is currently dominated by branded drugs, generics and over-thecounter (OTC) medications. These drugs aim at providing symptomatic relief for allergic rhinitis. Intranasal corticosteroids and antihistamine classes of drugs constitute the mainstay of the modern management of allergic rhinitis. Intranasal corticosteroids and antihistamines are considered as the first-line and secondline treatment option respectively for moderate to severe allergic rhinitis. These drugs have proven to be efficacious and safe for the treatment of allergic rhinitis and therefore, the allergic rhinitis therapeutics market is well served by these approved drugs. The only limitation of these drugs is that they do not target the root-cause of the disease. Therefore, innovative immunotherapies acting as the disease-modifying agents can gain a significant market share.

Pipeline Dominated by Immunotherapies Targeting Various Allergens Offers Hope

An analysis shows that immunotherapeutic products in development constitute 21% of the total 2011 allergic rhinitis pipeline and the immunotherapeutic class is largely focused on the oral sublingual tablet formulations. As immunotherapy is the only treatment option for allergic rhinitis with a diseasemodifying potential, large-scale development programs are being conducted which are primarily driven by new guidelines and changing regulations. Therefore, these innovative therapies are expected to promote the growth of allergic rhinitis therapeutics market in the future.